ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Jefferies Adjusts Price Target on Arrowhead Pharmaceuticals to $103 From $100, Maintains Buy Rating

11/23/2021 | 12:03pm EDT


© MT Newswires 2021
All news about ARROWHEAD PHARMACEUTICALS, INC.
05/13B. Riley Lowers Arrowhead Pharmaceuticals' PT to $82 from $106 to Account for Higher Re..
MT
05/12TRANSCRIPT : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/12NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
05/11Piper Sandler Lowers Arrowhead Pharmaceuticals Price Target to $72 From $89, Maintains ..
MT
05/11Chardan Lowers Arrowhead Pharmaceuticals Price Target to $80 From $94, Maintains Buy Ra..
MT
05/11Inflation: Have we passed the peak yet?
05/11ANALYST RECOMMENDATIONS : Electronic Arts, Corning, Arrowhead Pharma, Tesla, Wynn Resorts...
05/11Baird Upgrades Arrowhead Pharmaceuticals to Outperform From Neutral, Cuts Price Target ..
MT
05/10TRANSCRIPT : Arrowhead Pharmaceuticals, Inc., Q2 2022 Earnings Call, May 10, 2022
CI
05/10ARROWHEAD PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
More news
Analyst Recommendations on ARROWHEAD PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 304 M - -
Net income 2022 -105 M - -
Net cash 2022 453 M - -
P/E ratio 2022 -31,4x
Yield 2022 -
Capitalization 3 616 M 3 616 M -
EV / Sales 2022 10,4x
EV / Sales 2023 12,0x
Nbr of Employees 329
Free-Float -
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | ARWR | US04280A1007 | MarketScreener
Technical analysis trends ARROWHEAD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 35,15 $
Average target price 80,08 $
Spread / Average Target 128%
EPS Revisions
Managers and Directors
Christopher Richard Anzalone President, Chief Executive Officer & Director
Kenneth Allen Myszkowski Chief Financial Officer
Douglass B. Given Chairman
Javier San Martin Chief Medical Officer
Jeff Ketelhut Vice President-Information Technology & Systems
Sector and Competitors
1st jan.Capi. (M$)
ARROWHEAD PHARMACEUTICALS, INC.-48.42%3 616
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-19.12%41 409
BIONTECH SE-39.08%38 169